Home Compare BMRN vs EXAS
Stock Comparison · Structural lead, mixed market

BioMarin Pharmaceutical vs Exact Sciences: Which Stock Looks Stronger in 2026?

BioMarin Pharmaceutical holds the cleaner structural position, with growth as the main driver and profitability adding further support. Exact Sciences still has the edge on growth, which keeps the comparison from looking entirely one-sided. In the market, Exact Sciences carries the stronger setup — intact trend against BioMarin Pharmaceutical's broken trend. That leaves a split case: the structural lead stays with BioMarin Pharmaceutical, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Growth points more clearly toward Exact Sciences Corp, even if the broader score still leans toward BioMarin Pharmaceutical Inc..

Trajectory Similarity
0.66
Moderately similar
Peer-set rank: #4
within BioMarin Pharmaceutical Inc.'s functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The strongest overlap appears in revenue growth trajectory and margin trend.

Similarity drivers
revenue growth trajectorymargin trend
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
BMRN
BioMarin Pharmaceutical Inc.
47
Peer-Score
Signal qualityHigh
vs
EXAS
Exact Sciences Corp
33
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: BMRN vs EXAS Profitability 48 3 Stability 42 30 Valuation 56 33 Growth 36 83 BMRN EXAS
Gap Ranking
#1 Growth +47
#2 Profitability +45
#3 Valuation +23
#4 Stability +12
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BMRN and EXAS Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BMRNEXAS Relative valuation Structural strength

Structure stays fairly close here, while current pricing still looks more supportive for BioMarin Pharmaceutical Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) and Forward P/E where available.

Relative Position vs Comparable Companies
Growth
Exact Sciences Corp ranks near the top of the group on growth; BioMarin Pharmaceutical Inc. sits in the weaker half.
Profitability
Profitability also leans toward BioMarin Pharmaceutical Inc., reinforcing the broader structural lead.
Growth — Dominant Gap
BMRN
36
EXAS
83
Gap+47in favour of EXAS

The current lead is backed by a stronger multi-year growth trajectory.

What keeps the gap from being one-sided

On the market side, Exact Sciences carries the stronger trend while BioMarin Pharmaceutical's trend has broken — the market setup does not confirm the structural advantage.

What this means for the comparison

Growth is the clearest driver of the lead, with profitability adding further support — though growth still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the BMRN vs EXAS comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how BMRN and EXAS each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.